A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.

Aged Aged, 80 and over Antibodies, Monoclonal Antibodies, Monoclonal, Humanized / pharmacokinetics Antineoplastic Agents Antineoplastic Agents, Immunological / pharmacokinetics Ephrin-A2 / immunology Humans Male Middle Aged Neoplasms / diagnostic imaging Receptor, EphA2 / drug effects Tissue Distribution
89Zr-DS-8895a DS-8895a EphA2 Imaging

Journal

Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330

Informations de publication

Date de publication:
08 2022
Historique:
received: 14 12 2021
accepted: 15 03 2022
pubmed: 12 4 2022
medline: 20 7 2022
entrez: 11 4 2022
Statut: ppublish

Résumé

Ephrin type-A 2 (EphA2) is a transmembrane receptor expressed in epithelial cancers. We report on a phase I dose escalation and biodistribution study of DS-8895a, an anti-EphA2 antibody, in patients with advanced EphA2 positive cancers. DS-8895a was administered at 1, 3, 10 or 20 mg/kg every 2 weeks to determine safety, pharmacokinetics and anti-tumor efficacy. All patients underwent

Identifiants

DOI: 10.1007/s10637-022-01237-3 PMID: 35404015
pubmed: 35404015
doi: 10.1007/s10637-022-01237-3
pii: 10.1007/s10637-022-01237-3
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Monoclonal, Humanized 0
Antineoplastic Agents 0
Antineoplastic Agents, Immunological 0
EPHA2 protein, human 0
Ephrin-A2 0
Receptor, EphA2 EC 2.7.10.1

Banques de données

ClinicalTrials.gov
['NCT02252211']

Types de publication

Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

747-755

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Hasegawa J et al (2016) Novel anti-EphA2 antibody, DS-8895a for cancer treatment. Cancer Biol Ther 17(11):1158–1167
doi: 10.1080/15384047.2016.1235663
Burvenich IJ et al (2016) Molecular imaging and quantitation of EphA2 expression in Xenograft models with 89Zr-DS-8895a. J Nucl Med 57(6):974–980
doi: 10.2967/jnumed.115.169839
Easty DJ, Herlyn M, Bennett DC (1995) Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 60(1):129–136. https://doi.org/10.1002/ijc.2910600119
doi: 10.1002/ijc.2910600119 pubmed: 7814145
Nemoto T et al (1997) Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 65(4):195–203. https://doi.org/10.1159/000164123
doi: 10.1159/000164123 pubmed: 9396043
Rosenberg IM et al (1997) Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol 273(4):G824–G832. https://doi.org/10.1152/ajpgi.1997.273.4.G824
doi: 10.1152/ajpgi.1997.273.4.G824 pubmed: 9357823
Zelinski DP et al (2001) EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Can Res 61(5):2301–2306
Walker-Daniels J et al (1999) Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41(4):275–280. https://doi.org/10.1002/(sici)1097-0045(19991201)41:4%3c275::aid-pros8%3e3.0.co;2-t
doi: 10.1002/(sici)1097-0045(19991201)41:4<275::aid-pros8>3.0.co;2-t pubmed: 10544301
Ciprotti M et al (2015) Phase I imaging and pharmacodynamic trial of CS-1008 in patients with metastatic colorectal cancer. J Clin Oncol 33(24):2609
doi: 10.1200/JCO.2014.60.4256
Shitara K et al (2019) Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EphA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors. J Immunother Cancer 7(1):219
doi: 10.1186/s40425-019-0679-9
Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European j cancer 45(2):228–247
Scott AM et al (2020) First clinical study of a pegylated diabody 124 I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. Theranostics 10(25):11404–11415
doi: 10.7150/thno.49422
Scott AM et al (2005) A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 11(13):4810–4817
doi: 10.1158/1078-0432.CCR-04-2329
Scott AM et al (2007) A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci 104(10):4071–4076
doi: 10.1073/pnas.0611693104
Herbertson RA et al (2014) Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. J Nucl Med 55(4):534–539
doi: 10.2967/jnumed.113.132761
Herbertson RA et al (2009) Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers. Clin Cancer Res 15(21):6709–6715
doi: 10.1158/1078-0432.CCR-09-0536
Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46(6):1023–1027
pubmed: 15937315
Valentin J (2007) International Commission on Radiological Protection. The 2007 recommendations of the international commission on radiological protection. Annals of the ICRP, ICRP Publication 103:2–4
Bolch W et al (2016) ICRP publication 133: The ICRP computational framework for internal dose assessment for reference adults: specific absorbed fractions. Ann ICRP 45(2):5–73
doi: 10.1177/0146645316661077
Heskamp S et al (2017) 89Zr-immuno-positron emission tomography in oncology: state-of-the-art 89Zr radiochemistry. Bioconjug Chem 28(9):2211–2223
doi: 10.1021/acs.bioconjchem.7b00325
Lamberts LE et al (2015) Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol 33(13):1491–1504
doi: 10.1200/JCO.2014.57.8278
van de Donk PP et al (2020) Molecular imaging biomarkers for immune checkpoint inhibitor therapy. THERANOSTICS 10(4):1708–1718
doi: 10.7150/thno.38339
Carrasquillo JA et al (2019) Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. J Nucl Med 60(11):1517–1523
doi: 10.2967/jnumed.118.222844
Jauw YW et al (2019) Interobserver reproducibility of tumor uptake quantification with 89 Zr-immuno-PET: a multicenter analysis. Eur J Nucl Med Mol Imaging 46(9):1840–1849
doi: 10.1007/s00259-019-04377-6

Auteurs

Hui K Gan (HK)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia. hui.gan@onjcri.org.au.
School of Cancer Medicine, La Trobe University, Melbourne, Australia. hui.gan@onjcri.org.au.
Department of Medical Oncology, Austin Health, Melbourne, Australia. hui.gan@onjcri.org.au.
ORCID: 0000-0001-7319-8546

Sagun Parakh (S)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Department of Medical Oncology, Austin Health, Melbourne, Australia.

F T Lee (FT)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.

Niall C Tebbutt (NC)

Department of Medical Oncology, Austin Health, Melbourne, Australia.

Malaka Ameratunga (M)

Department of Medical Oncology, Austin Health, Melbourne, Australia.

Sze Ting Lee (ST)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
Faculty of Medicine, University of Melbourne, Melbourne, Australia.

Graeme J O'Keefe (GJ)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.

Sylvia J Gong (SJ)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.

Christine Vanrenen (C)

Department of Medical Oncology, Austin Health, Melbourne, Australia.

Jaren Caine (J)

Department of Medical Oncology, Austin Health, Melbourne, Australia.

Mara Giovannetti (M)

Ludwig Cancer Research, New York, NY, USA.

Carmel Murone (C)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.

Fiona E Scott (FE)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, Australia.

Nancy Guo (N)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.

Ingrid J G Burvenich (IJG)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, Australia.

Cameron Paine (C)

Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.

Mary J Macri (MJ)

Ludwig Cancer Research, New York, NY, USA.

Masakatsu Kotsuma (M)

Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.

Giorgio Senaldi (G)

Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.

Ralph Venhaus (R)

Ludwig Cancer Research, New York, NY, USA.

Andrew M Scott (AM)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
Faculty of Medicine, University of Melbourne, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › A phase 1 safety and bioimaging trial of...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › A phase 1 safety and bioimaging trial of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › A phase 1 safety and bioimaging trial of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › A phase 1 safety and bioimaging trial of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › A phase 1 safety and bioimaging trial of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › A phase 1 safety and bioimaging trial of...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Éphrines › Éphrine A2 › A phase 1 safety and bioimaging trial of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A phase 1 safety and bioimaging trial of...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › A phase 1 safety and bioimaging trial of...
questionsmedicales.fr › Tumeurs › A phase 1 safety and bioimaging trial of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs à activité tyrosine kinase › Famille des récepteurs Eph › Récepteur EphA2 › A phase 1 safety and bioimaging trial of...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Distribution tissulaire › A phase 1 safety and bioimaging trial of...